Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 04, 2022

Thromboembolic Events in Patients With HER2-Negative, HR-Positive Metastatic Breast Cancer Treated With Ribociclib Plus Letrozole or Fulvestrant

Cancer management and research

 

Additional Info

Cancer management and research
Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
Cancer Manag Res 2022 Mar 01;14(xx)1033-1041, H Abdel-Razeq, B Sharaf, R AlMasri, R Abdel-Razeq, F Tamimi, O Khader, O Salama, M Abunasser, S Edaily, H Abdulelah

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading